Vaccine
Talk
(Egyptian Edition)
"Everything you need to know about
vaccines in Egypt"
(Egyptian Edition)
"Everything you need to know about
vaccines in Egypt"
Content added: APRIL 29, 2026
Last updated: APRIL 29, 2026
Reinfection appears to be uncommon but does occur. Reinfection may present as a persistent cough rather than typical pertussis.
Yes. Adolescents or adults who have a history of pertussis disease generally should receive Tdap according to the routine recommendation. This practice is recommended because the duration of protection induced by pertussis disease is unknown (waning might begin as early as 7 years after infection) and because diagnosis of pertussis can be difficult to confirm.
Tdap vaccination status does not change the approach to evaluating postexposure prophylaxis when HCWs are exposed to pertussis. Tdap vaccines have an uncertain role in the prevention of transmission of pertussis and herd protection. Antipertussis antibody levels begin to decline precipitously after the first year following a single Tdap vaccination. Healthcare facilities should follow the post-exposure prophylaxis protocol for pertussis exposure. HCW can either receive postexposure prophylaxis or be carefully monitored for 21 days after pertussis exposure.
All children should receive a series of DTaP at ages 2, 4, and 6 months, with boosters at ages 15-18 months and at 4-6 years. The fourth dose may be given as early as age 12 months if at least 6 months have elapsed since the third dose.
A listing of the recommendations follows:
Vaccine efficacy is 80%-85% following 3 doses of DTaP vaccine. Efficacy data after 1 or 2 doses are likely lower. The most effective way to prevent pertussis in early infancy is maternal Tdap vaccination during each pregnancy, preferably between 27 and 36 weeks. CDC evaluation found maternal vaccination in the third trimester prevents 78% of pertussis cases in infants younger than 2 months and reduces infant hospitalization risk by 90%.
Yes. ACIP states that a child who receives Tdap at age 7-9 years as part of catch-up should receive another dose of Tdap at age 11 or 12 years.
No. The minimum interval between second and third tetanus-containing doses is 6 calendar months. The pertussis component of Tdap counts, but the Td component is invalid. Give Td or Tdap 6 months after the invalid Tdap dose.
If the first tetanus-toxoid dose is administered before the first birthday, 4 doses are needed before starting the 10-year booster cycle. If first dose is after the first birthday, 3 doses are needed. Final dose should be spaced 6 months from the previous dose.
Give the booster dose 10 years later, unless needed sooner for wound prophylaxis or pregnancy.
Yes. Tetanus disease does not produce reliable immunity. Give Tdap now if no contraindications. If prior vaccination is undocumented, complete a 3-dose primary series (Tdap, then Td/Tdap 4-8 weeks later, then Td/Tdap 6-12 months after dose 2).
No. Tdap should be administered as soon as possible.
No. If Tdap is administered earlier in pregnancy, do not repeat it. Only one dose is recommended during each pregnancy.
Children younger than 7 years use DTaP or DT; older children/adults use Tdap or Td. Pediatric formulations use uppercase D (DTaP, DT) because they contain more diphtheria component. Adult formulations use lowercase d (Tdap, Td). Tetanus component remains uppercase T in all products.
Use whatever DTaP vaccine is available for subsequent doses.
If given under age 7 as dose 1, 2, or 3, it is not valid and must be repeated with DTaP. If given as dose 4 or 5, it can count as valid.
Yes. A second Tdap should be given at age 11 or 12 years.
Yes. A CDC study showed a small increased febrile seizure risk in 24 hours after concomitant administration with PCV13 or DTaP, but overall risk is small and ACIP recommends same-visit administration when indicated.
No. There is no upper age limit for Tdap vaccination.
Count the dose as Tdap. No repeat dose is needed, but implement steps to prevent administration errors.
Optimally between 27 and 36 weeks' gestation, preferably in the early part of that window; however, it can be given at any time during pregnancy.
Tdap can be given at any interval after Td and preferably between 27 and 36 weeks' gestation.
If dose #4 was at least 4 months after dose #3 and at age 12 months or older, it does not need repeating, though a 6-month interval is preferred.
Contraindications include severe allergic reaction to a vaccine component or prior dose. Encephalopathy within 7 days of a previous pertussis-containing vaccine not due to another cause is a contraindication to DTaP and Tdap.
It depends. If prior severe allergic reaction or encephalopathy after DTaP/DTP occurred, give Td instead of Tdap. For precautions, delay or weigh risk-benefit as clinically appropriate.
Yes. Controlled epilepsy is not a contraindication to Tdap.
Further evaluation is needed. Delay DTaP/DT until neurologic condition is evaluated and stabilized. Other indicated vaccines may continue. Decision on DTaP vs DT should be made no later than the first birthday.
No. Tetanus toxoid has never contained horse serum or protein.
Wounds, especially punctures or contaminated wounds, should be managed as soon as possible. Urgency depends on wound type and susceptibility to tetanus. Unvaccinated people with tetanus-prone wounds need Td/Tdap plus TIG promptly.
TIG is recommended for any wound other than clean minor wounds when vaccination history is unknown or incomplete (fewer than 3 doses). People with HIV or severe immunodeficiency and contaminated wounds should also receive TIG regardless of vaccine history. Give as soon as possible.
Tetanus incubation is typically 3-21 days. Expert opinion suggests little benefit in giving TIG more than about 1 week after injury in previously vaccinated people not up to date. For people believed completely unvaccinated, TIG may still be considered up to 3 weeks after injury. Td or Tdap should be given concurrently with TIG.